Virtual Webinar
CRISPR-Cas9 holds incredible promise for treating thousands of genetic disorders—but ensuring these therapies are both potent and safe is a major challenge. In this on-demand webinar from Active Motif and Eclipsebio, we break down the latest sequencing-based strategies for thoroughly characterizing CRISPR-Cas9 therapies.Dr. Wayne Doyle, Head of Platform at Eclipsebio, showcased how our eMERGE platform delivers actionable insights into impurities and therapeutic potency and Dr. Katelyn Mortenson, Epigenetics Services Scientist from Active Motif, demonstrated how their DISCOVER-Seq assay precisely maps off-target editing events.
Click here to watch the recording.
Summary
Purpose:
Discover sequencing-based methods for characterizing CRISPR-Cas9 therapies
Presenters:
Dr. Wayne Doyle (Head of Platform)
Dr. Katelyn Mortenson (Applications Scientist)
Date:
02 / 20 / 25